Stay informed on developments in cancer and oncology diagnosis, prevention and treatment through these curated webinars. As the race toward a cure for cancer continues, advances in cancer research are constantly revealed as innovation in the field of oncology progresses.
We recently determined that concurrent inhibition of autophagy, using the lysosomal inhibitor chloroquine (CQ), and of ERK, using a small molecule ERK inhibitor (ERKi), synergistically suppr...
Neoantigens are peptides derived from patient-specific and tumor-specific mutations, which can be recognized by the immune system and mediate tumor recognition that leads to immune destructi...
The future of cancer care is contingent on better understanding of molecular, clinical, and outcome data. This can be achieved by leveraging collaborative affiliations and networks locally a...
Over the past 10 years, we have come to a greater understanding of the pathogenesis of men who succumb to prostate cancer. One critical aspect is the role of molecular drivers in patients wi...
Discover how experience in utilizing a digital lab platform can elevate research workflows. Margriet will share insights, practical strategies, and success stories that demonstrate the benef...
Data suggests that genetics comprises 42-58% of the prostate cancer risk. GWAS has found about 43% of the risk SNPs in Blacks and European Americans. Most of the SNPs that have been discover...
Bromodomains (BRDs) are evolutionarily conserved protein domains that interact with acetylated histones and set off a chain of events that includes recruiting transcription factors and other...
Key to precision oncology is the development of expert databases that organize and standardize information on cancer-related genetic variants, as well as their associated diagnostic, prognos...
Technological advances in Artificial Intelligence (AI), particularly deep learning, have demonstrated remarkable progress in image-recognition tasks. Methods ranging from convolutional neura...
Genomic research has long been skewed toward European populations, leading to significant underrepresentation of Non-European groups in both research studies and genomic databases. This bias...
Racial and ethnic minorities often experience cancer disparities in the United States with higher disease prevalence, shorter survival, and higher death rates with many cancer types. These d...
What happens when pharma and flow cores face the same challenge — doing more with less? Join Ryan Duggan (AbbVie) and David Leclerc (President, GLIIFCA) for a balanced discussion on h...
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
One of the central tenants of biology is that our genetics—our genotype—influences the physical characteristics we manifest—our phenotype. But with more than 25,000 human g...
The microenvironment of many solid tumors impedes many immunotherapeutic treatments by inhibiting the effector functions of many classes of anti-tumor immune cells, including effector T cell...
In the United States, cancer disproportionately impacts Black and African American individuals. Identifying genetic factors underlying cancer disparities has been an important research focus...
There are currently several different FDA approved radiopharmaceuticals being used in both large academic and small practice settings to accurately stage and identify local and metastatic pr...
Uterine leiomyosarcoma (uLMS) is a rare aggressive sarcoma of the smooth muscle layer of the uterus manifested in high local recurrence and metastatic rate. Currently, effective treatment of...
Individuals with Lynch syndrome (LS) are prone to develop early-onset mismatch repair deficient (dMMR) colorectal- and endometrial cancers due to germline pathogenic variants (PVs) in one of...
Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that i...
Non-small cell lung cancer (NSCLC) accounts for more deaths than colon, breast, and prostate cancers combined. Of patients with NSCLC, 20% initially present with stage I or II disease, for w...
Jeff Borgia, Ph.D. is the Director of the Rush Cancer Center Biorepository, where he oversees the collection and annotation of patient specimens in support of ongoing translational research...
To determine efficacy of specific complementary therapies to advance evidence-based, integrative healthcare, the complementary modality should first be introduced to stakeholders to determin...
Learning Objectives: 1. Classify the obstacles to successful manufacturing of antigen-specific T-cells in immunotherapy. 2. Highlight the effects of CD45RA+ subsets in expansion of antigen-s...
Learning Objectives: 1. Explain how obesity impacts the survival of pediatric patients with specific subtypes of leukemia. 2. Describe how obesity impacts T-cell function in pediatric popula...
The ultimate promise of tumor immunotherapy is dependent on the generation of effective immunity against cancer, including CD4 and CD8 T cell responses. However, activating T cells in cancer...
One of the central tenets of biology is that our genetics—our genotype—influences the physical characteristics we manifest—our phenotype. But with more than 25,000 human ge...
We recently determined that concurrent inhibition of autophagy, using the lysosomal inhibitor chloroquine (CQ), and of ERK, using a small molecule ERK inhibitor (ERKi), synergistically suppr...
![Anti-PRAME antibody [EPR20330]](https://d3bkbkx82g74b8.cloudfront.net/eyJidWNrZXQiOiJsYWJyb290cy1pbWFnZXMiLCJrZXkiOiJjb21wYW55X3Byb2R1Y3RfcHJvZmlsZV9pbWFnZV9mMzEwNTY4MGY1NmVmZjU3ZjZhMWRkZTU2M2Q4YjBmODZjMDJkNDE4XzMwMDA3MTg1ODEyLmpwZyIsImVkaXRzIjp7InRvRm9ybWF0IjoianBnIiwicmVzaXplIjp7IndpZHRoIjozMDAsImhlaWdodCI6MzAwLCJmaXQiOiJjb3ZlciIsInBvc2l0aW9uIjoiY2VudGVyIiwiYmFja2dyb3VuZCI6IiNmZmYifSwiZmxhdHRlbiI6eyJiYWNrZ3JvdW5kIjoiI2ZmZiJ9fX0=)
